JYNT
The Joint Corp.8.93
+0.15+1.71%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
New patients bottleneck; pricing pilots promising.
Q&A zeroed in on new patient acquisition as the core comp sales drag, with conversion and attrition holding up slightly better year-over-year, while early marketing shifts show sequential lead and traffic gains but no inflection yet. Management detailed pricing pilots favoring $10 hikes across 300 clinics yet excluded them from 2026 guidance amid macro pressures on $60,000-$110,000 household incomes. They unveiled AlignOne ($35 monthly minimum) and AlignTwo tests to curb low-frequency attrition, plus a new ops leader driving clinic conversion training. Growth capex targets 3% of revenue at 25% IRR, focused on MarTech and coordinator UI. Comps trended worst in November, best December; January/February similar. Cautious tone persists—investors will eye H2 traction.
Key Stats
Market Cap
135.63MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
8-K
Sells 22 SE clinics, scraps CA deal
The Joint Corp. signed an asset purchase agreement on December 5, 2025, to sell 22 company-owned or managed clinics in Virginia, North Carolina, and South Carolina to existing franchise community members for $1,482,800, comprising $1M cash, $667,800 prorated franchise fees, and a $185,000 renovation credit. Buyers paid $100,000 down, with the balance via promissory notes at closing, conditioned on lease assignments for at least 17 clinics. It terminated a prior $4.5M deal for 45 California clinics on December 11 due to unmet conditions. Franchisees take over operations mid-December.
8-K
Sells 45 clinics, boosts buybacks
The Joint inked an asset purchase deal on November 2 to sell 45 Southern California clinics to Elite Chiro Group for $4.5 million—$3.2 million cash plus $1.3 million prorated franchise fees—advancing its pure-play franchisor shift. Q3 revenue hit $13.4 million, up 6%, with consolidated Adjusted EBITDA jumping 36% to $3.3 million. Board added $12 million to repurchases, now through 2027. Terms still under negotiation.
8-K
Clinic refranchising approved
The Joint Corp. secured lender consent on September 30, 2025, to refranchise all company-owned clinics by December 31, 2025, while extending its revolving credit maturity to August 31, 2027. This one-time waiver sidesteps covenant breaches, requiring sales at fair value with at least 75% cash and zero outstanding loans during transactions. Refranchising sharpens focus on franchising, yet demands swift execution amid negative earnings realities.
8-K
CFO separation agreement finalized
The Joint Corp. finalized a separation agreement on August 22, 2025, with former CFO Jake Singleton, whose role ended June 9, 2025. The deal provides $171,958.50 in severance, $36,193.99 for accumulated time off, $15,000 additional cash, and up to six months of COBRA coverage, in exchange for a full release of claims. Equity awards follow existing terms without acceleration. This resolves the exit cleanly, minimizing disputes.
10-Q
Q2 FY2025 results
The Joint Corp. posted solid Q2 FY2025 results from continuing operations, with total revenues climbing 5.2% y/y to $13.3M on stronger royalty fees and franchise growth, while narrowing its operating loss by 36% y/y to $1.1M amid tighter cost controls. Gross margins held steady at 79.1%, up slightly from 77.7% y/y, as franchise and IT costs dipped 1.4% y/y. Diluted EPS from continuing operations improved to -$0.06 from -$0.11 y/y, reconciling neatly with 15.4M weighted shares. Cash swelled to $29.8M at quarter-end, bolstered by $7.8M from clinic sales under its refranchising push, which closed 37 locations including a $8.3M Arizona/New Mexico cluster deal recognizing no goodwill but freeing up resources. Free cash flow wasn't disclosed in the 10-Q. Yet competition from established chiropractic rivals lingers as a key risk.
IPO
Website
Employees
Sector
Industry
BTMD
Biote Corp.
2.67+0.05
CDIX
Cardiff Lexington Corporation
1.42-0.29
DYNT
Dynatronics Corp.
0.04+0.00
FCHS
First Choice Healthcare Solutio
0.01+0.00
HLYK
HealthLynked Corp.
1.67-0.22
HNGE
Hinge Health, Inc.
48.41-0.09
JRSS
JRSIS Health Care Corp
0.02+0.00
PAIYY
Aesthetic Medical International
0.13+0.00
PIII
P3 Health Partners Inc.
4.59-0.36
YJGJ
Yijia Group Corp.
1.61+0.00